Thus, stratification of SLE patients of non‐European ancestry by low IFN score and low antibody disease burden (as in cluster NEA‐1) isolates a rituximab‐resistant patient subset, potentially with least B cell–dominant disease. The gene discussed is IFNA1; the disease is systemic lupus erythematosus.